Direct interactions between pro-and anti-apoptotic BCL-2 family members form the basis of cell death decision-making at the outer mitochondrial membrane (OMM). Here we report that three anti-apoptotic BCL-2 proteins (MCL-1, BCL-2 and BCL-XL) found untethered from the OMM function as transcriptional regulators of a prosurvival and growth program. Anti-apoptotic BCL-2 proteins engage a BCL-2 homology (BH) domain sequence found in SUFU (suppressor of fused), a tumour suppressor and antagonist of the GLI DNA-binding proteins. BCL-2 proteins directly promote SUFU turnover, inhibit SUFU-GLI interaction, and induce the expression of the GLI target genes BCL-2, MCL-1 and BCL-XL. Anti-apoptotic BCL-2 protein/SUFU feedforward signalling promotes cancer cell survival and growth, and can be disabled with BH3 mimetics-small molecules that target anti-apoptotic BCL-2 proteins. Our findings delineate a chemical strategy for countering drug resistance in GLI-associated tumours and reveal unanticipated functions for BCL-2 proteins as transcriptional regulators.
Programmed cell death or apoptosis extensively contributes to animal development and physiology by promoting the timely turnover of unwanted or compromised cells. Cell death decisions are largely governed by the localized action of the B-cell lymphoma 2 (BCL-2) family of proteins at the OMM. The interaction between anti-and pro-apoptotic BCL-2 family members mediated by BH domains found in these proteins determines the activity of BAK and BAX-two pro-apoptotic BCL-2 proteins that permeabilize the OMM. Ensuing cytoplasmic cytochrome C leakage and the assembly of an apoptosome complex is generally recognized as the point of no return for cell death commitment 1,2 . The stoichiometry of anti-and pro-apoptotic BCL-2 family members at the OMM thus dictates cellular response thresholds to intrinsic and extrinsic apoptotic signals 2 . Chemicals that target anti-apoptotic (henceforth prosurvival) BCL-2 proteins are in clinical development as anti-leukaemic agents 3 .
The Hedgehog (HH) proteins play pivotal roles in body patterning and organogenesis in part by controlling expression of apoptosis regulatory proteins such as BCL-2 (refs 4-9) . Deviant activation of HH signalling is associated with several cancers including medulloblastoma and basal cell carcinoma (BCC) 10, 11 . Cellular response to HH proteins is initiated following their binding to the multi-pass protein Patched 1 (PTCH1), a suppressor of the Smoothened (SMO) seven transmembrane receptor (reviewed in ref. 12) ( Fig. 1a ). SMO is the target of FDA-approved anti-cancer agents used in the management of metastatic BCC 13 . Activated SMO promotes SUFU disassociation from GLI proteins thus allowing them to activate transcription 14, 15 .
Much of our understanding of cell death regulation stems from studies focused on BCL-2 family proteins at the OMM 1 , but prosurvival BCL-2 proteins have recently seen expanded functions at other organellar sites 16, 17 . Here, we describe a direct role of Fcgr4 Exosc5
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Epb4. Ctrl Bclxl -/-Genotype: Figure 1 Prosurvival BCL-2 proteins collectively promote GLI signalling by suppressing the activity of the tumour suppressor SUFU. (a) Site of action for HH pathway antagonists. Mutations in PTCH1 unleash constitutive SMO activity in BCC and medulloblastoma. SMO mutations or increased GLI expression promotes drug resistance. (b) A cultured-cell-based screen for identifying GLI transcription regulators. FL, firefly luciferase; RL, Renilla luciferase. GLI-binding enhancers in the GLI-BS reporter report GLI activity. (c) Identification of genes that promote HH signalling using the Mammalian Gene Collection cDNA library. C3H10T1/2 cells were transfected in duplicate experiments (biological replicates) with a single cDNA and reporters in b. Genes that induce FL/RL activity greater than 4 × s.d. from the mean are labelled. Green, known HH pathway components. (d) Smo −/− or Kif3a −/− MEFs were stained with an anti-acetylated tubulin antibody to visualize primary cilia (arrows). Scale bars, 10 µm. (e) MCL-1 induces HH pathway activity independently of SMO and primary cilia. Candidate HH pathway activators were evaluated for GLI-inducing activity in Smo −/− or Kif3a −/− MEFs using the GLI-BS reporter (n = 3 independent measurements). (f) SUFU is essential for MCL-1-dependent HH pathway response. GLI2 but not MCL-1 or SMO siRNAs reduce GLI-BS reporter activity in Sufu −/− MEFs. All three siRNAs reduced reporter activity in WT cells expressing the SHH signalling domain (SHH-N) (n = 3 independent measurements). (g) MCL-1 loss increases total and phosphorylated SUFU. Mcl1 −/− MEFs were transfected with control or human Mcl-1 cDNA. Lysates were subjected to western blotting. SUFU-P antibody recognizes phospho-Ser342, a GSK3βdependent modification (n = 3 independent measurements). (h) Multiple prosurvival BCL-2 proteins induce GLI activity. DNAs encoding the indicated prosurvival BCL-2 proteins were evaluated for GLI activity induction using the GLI-BS reporter. SANT-1: SMO antagonist (n = 3 independent measurements). (i) Prosurvival BCL-2 proteins that promote GLI activity interact with SUFU. RMS13 cell lysates were subjected to IP with control or anti-SUFU antibody. (j) Bclxl −/− and Bcl2 −/− MEFs exhibit increased total and phosphorylated SUFU. All error bars represent mean ± s.d. Primary screen results are provided in Supplementary Table 1 . Source data are available in Supplementary Table 4 . Unprocessed original scans of blots are shown in Supplementary Fig. 7 . Statistical significance was calculated using Student's t-test, * P < 0.05, * * P < 0.01 and * * * P < 0.001.
prosurvival BCL-2 proteins in transcriptional regulation. SUFUmediated suppression of GLI activity is controlled by a BH3 sequencedependent interaction between SUFU and three prosurvival BCL-2 family members (MCL-1, BCL-2 and BCL-XL). We demonstrate that these interactions occur in the cytoplasm away from the OMM and that de-repressed GLI proteins in turn induce MCL-1, BCL-2 and BCL-XL expression as well as cell growth-promoting genes such as cyclin D1. Thus, the abundance of cytoplasmic prosurvival BCL-2 proteins functions as part of a feedforward transcriptional regulatory loop that controls prosurvival BCL-2 protein expression. We demonstrate that this signalling axis can be disengaged with prosurvival BCL-2 protein inhibitors (BH3 mimetics) to achieve predictable anti-cancer effects.
RESULTS
A gain-of-function screen identifies the prosurvival MCL-1 protein as an instigator of GLI transcriptional activity Murine C3H10T1/2 fibroblasts express core HH pathway components, elaborate a primary cilium that is essential for ligandmediated signalling, and exhibit robust response to exogenously supplied HH protein 18 . To identify genes capable of promoting GLI activity and that may be targeted to overcome drug resistance to SMO antagonists, we seeded C3H10T1/2 cells in 96-well culture plates and transfected a single complementary DNA (cDNA) from the Mammalian Gene Collection expression-ready cDNA library along with a HH-responsive firefly luciferase (FL) reporter (GLI-BS reporter) and a control Renilla luciferase (RL) reporter (SV40-RL) 19 ( Fig. 1b ). The ratio of FL/RL activity was determined 36 h later for each experiment and cDNAs inducing a signal greater than 4×s.d. from the mean were further considered ( Fig. 1c and Supplementary  Table 1 ). Several known HH regulators were also identified from this screen [20] [21] [22] [23] . We used mouse embryonic fibroblasts (MEFs) lacking SMO or the ability to form primary cilia (Kif3a −/− ) to identify direct regulators of GLI proteins ( Fig. 1d,e ). Three cDNAs when introduced into these cells retained their ability to induce the GLI-BS reporter: the HES family BHLH transcription factor 1 (HES1), Kruppel-like factor 4 (KLF4), and the prosurvival protein BCL-2 family member myeloid cell leukaemia 1 (MCL-1). We focus here on MCL1 given that it is amplified in ∼11% of all cancers 24 and has no previously assigned role in GLI regulation.
Prosurvival BCL-2 proteins disrupt SUFU repression of GLI activity
We first addressed the contribution of the GLI regulator SUFU to prosurvival BCL-2 protein-mediated GLI regulation (see Fig. 1a ). In contrast to control cells, Sufu −/− MEFs exhibited little change in GLI-BS reporter activity following introduction of Mcl-1 short interfering RNAs (siRNAs), suggesting that SUFU is the target of MCL-1 action (Fig. 1f ). The stability and activity of SUFU is regulated by sequential phosphorylation by PKA then GSK3β (ref. 25) . To evaluate the effects of targeting MCL-1 on SUFU abundance and phosphorylation, we compared fibroblasts derived from wild-type (WT) and Mcl1 −/− animals ( Fig. 1g ). Absence of Mcl1 resulted in increased total and phosphorylated SUFU but introduction of human MCL-1 into Mcl1 −/− cells restored total and phosphorylated SUFU levels to those observed in WT MEFs. The change in SUFU protein abundance is a not a consequence of altered SUFU transcript levels but rather mitigation of SUFU protein turnover by a proteasomedependent mechanism ( Supplementary Fig. 1a-d) .
We collected cDNAs corresponding to the remaining four prosurvival BCL-2 family members (BCL-2, BCL-XL, A1 and BCL-W) and compared their ability with that of MCL-1 to induce the GLI-BS reporter ( Fig. 1h and Supplementary Fig. 1e ). Notably, BCL-2 induced the GLI-BS reporter in our screen, albeit not in a sufficiently robust manner to be included as a first-pass hit (see Supplementary Table 1) . Overexpression of three out of five prosurvival BCL-2 proteins promoted GLI activity in a SMO-independent manner. Given the functional interaction of MCL-1 with SUFU, we surmised that the prosurvival proteins that promote GLI activity are found in a complex with SUFU. Indeed, using an immunoprecipitation (IP) approach, we observed only the three anti-apoptotic proteins that promoted GLI activity to be found in a complex with SUFU ( Fig. 1i and Supplementary Fig. 1f ). Finally, we observed using Bcl2-or Bclxl-null cells that loss of either of these proteins as in the case of MCL-1 resulted in increased abundance of total and phosphorylated SUFU, thus revealing a common target for all three prosurvival BCL-2 proteins ( Fig. 1j and Supplementary Fig. 1g ). We also showed that the ability of an overexpressed prosurvival BCL-2 family member to interact with SUFU correlates with its ability to induce changes in SUFU abundance ( Supplementary Fig. 1h ).
SUFU harbours a BH3 sequence that mediates interaction with prosurvival BCL-2 proteins
Our findings suggest a direct interaction between SUFU and multiple BCL-2 proteins. To better understand the basis for the SUFU-MCL-1 interaction, we mapped the determinants in MCL-1 required for SUFU binding ( Fig. 2a and Supplementary Fig. 2a,b ). At the same time, we also determined the ability of the various mutant MCL-1 proteins to overcome SUFU-mediated GLI inhibition using the GLI-BS reporter ( Supplementary Fig. 2c ). These results taken together reveal that mutations compromising the integrity of the BCL-2 core (BC) in MCL-1 eliminated the ability of MCL-1 to bind to and inactivate SUFU (see Fig. 2a ). Since the BC constitutes the BH3 sequence recognition module in interactions between prosurvival and pro-apoptotic BCL-2 family proteins, the observation implicates a previously undefined BH3 sequence in SUFU.
We similarly mapped MCL-1-binding sites in SUFU (see Fig. 2a and Supplementary Fig. 2d ,e). Two SUFU regions mediate MCL-1 binding: an amino-terminal sequence (amino acids 1-100) and a putative alpha helix adjacent to the PKA and GSK3β phosphorylation sites (amino acids 302-327). The latter binding site remarkably resembled the MCL-1 BH3 sequence, which constitutes a part of the MCL-1 BC and which is a high-affinity ligand for MCL-1 itself 26 . To determine whether the putative SUFU BH3 peptide indeed functions as a canonical BH3 sequence, we performed NMR titration with uniformly 15 N-labelled human MCL-1 and unlabelled SUFU BH3 (Fig. 2b,c ). Significant backbone 1 H-15 N chemical-shift perturbations were induced by the SUFU BH3 peptide but not dimethylsulfoxide (DMSO) at the MCL-1 BC groove ( Supplementary Fig. 2f ,g). The chemical shifts within this minor site are probably generated as a result of the major conformational change in the BC groove as we previously observed with other BH3 complexes of BCL-2 family proteins, including the BID BH3-MCL-1 (ref. 27 ) and BID BH3-BAK complexes 28 . Consistent with the involvement of the BH3 sequence in mediating SUFU and MCL-1 interaction, we observed stoichiometric interaction of the two proteins ( Supplementary Fig. 2h ). These structural studies delineate a mechanistic basis for recognition of SUFU by prosurvival BCL-2 proteins. 
5K * * Actin FL GL 150 37 75 HEK293 cell line: Supplementary  Table 4 . Unprocessed original scans of blots are shown in Supplementary  Fig. 7 . Statistical significance was calculated using Student's t-test, * * P < 0.01.
Two residues (Gly217 and Asp218) found in the MCL-1 BC have been previously shown to be essential for recognizing BH3 ligands 29 (see Fig. 2c ). We compared the ability of WT and G217E/D218A MCL-1 fusion proteins to interact with a well-established BH3-only protein (tBID) as well as SUFU ( Fig. 2d ). Whereas WT MCL-1 protein was able to bind both tBID and SUFU, the mutant protein failed to do so. At the same time, we demonstrated that a recombinant protein expressing the SUFU BH3 sequence is able to bind to the MCL-1 fusion protein ( Fig. 2e ). Furthermore, this interaction was dependent on an acidic residue in the SUFU BH3 sequence that corresponds to a residue essential to the binding capability of other BH3 sequences 26 . Finally, two small molecules that target the MCL-1 BC (MIM1 and MIMX) 30 were able to disrupt MCL-1/SUFU interaction ( Fig. 2f,g) . Using CRISPR-Cas9 genome editing, we generated from rhabdomyosarcoma-derived RMS13 cells a cell line harbouring a single protein encoding a SUFU allele with a 30-base-pair deletion corresponding to the loss of 10 amino acids from the BH3 sequence ( Fig. 2h ). We demonstrated by using a co-IP strategy that the SUFU BH3 protein no longer binds to prosurvival BCL-2 proteins ( Fig. 2i ). Taken together, our observations provide a molecular basis for MCL-1 recognition of SUFU.
MCL-1 regulates SUFU-GLI binding in a BH3 sequence-dependent fashion
The BH3 sequence and PKA/GSK3β phosphorylation sites fall within the IDR, a region that governs overall SUFU conformation and activity but that apparently is not accessible to crystallography 31, 32 . Deletion of the IDR does not abolish SUFU-GLI interaction but renders SUFU unresponsive to HH signal, suggesting that PKA/GSK3β phosphorylation controls SUFU activity by toggling the IDR conformation 33 . To test the hypothesis that MCL-1 may similarly control the IDR conformation either directly or indirectly by thwarting SUFU phosphorylation by PKA/GSK3β, we first established a cell line that provides quantitative reporting of SUFU/GLI interaction changes ( Fig. 2j ,k). Consistent with previous observations, we observed a decrease in SUFU/GLI association in cells treated with inhibitors of either PKA or GSK3β (Fig. 2l ). On the other hand, gain or loss of MCL-1 function decreased and increased SUFU/GLI interactions, respectively. At the same time, an in vitro kinase assay using purified proteins reveals that MCL-1 prevents SUFU phosphorylation by PKA ( Supplementary Fig. 2i ,j). These observations suggest that prosurvival proteins such as MCL-1 leverage local changes in IDR structure either directly or indirectly by blunting PKA/GSK3β phosphorylation to control SUFU responsiveness to HH.
Feedforward signalling mediated by prosurvival BCL-2 proteins is required for HH response
Our observations suggest that previously described HH-induced transcription of BCL2 may constitute an unrecognized feedforward signalling mechanism 31, 32 . To determine whether other prosurvival BCL-2 family transcripts may be induced by GLI activation, we examined the abundance of prosurvival Bcl2 family messenger RNAs and protein in C3H10T1/2 cells co-transfected with SHH DNA or treated with the SMO agonist SAG (Fig. 3a,b and Supplementary Fig. 3a ). With either mechanism of inducing GLI activity, we observed increases in Bcl2, Mcl1 and Bclxl mRNA and protein, suggesting that GLI regulates only the SUFU-interacting members of the prosurvival BCL-2 family. The expression levels of BCL2 and MCL1 are also elevated in vivo in a comparison of medulloblastoma samples belonging to the 'SHH' subgroup (predominantly driven by mutations in PTCH1) and normal cerebellar tissue ( Supplementary Fig. 3b ).
The same three proteins that interact with SUFU (MCL-1, BCL-2 and BCL-XL) are able to induce expression of Ptch1, Bcl2 and Mcl1 when each prosurvival BCL-2 protein was overexpressed in C3H10T1/2 cells ( Fig. 3c ). We also demonstrated that this transcriptional response is GLI1/GLI2 dependent, can be suppressed by the BH3-only protein NOXA that binds to the MCL-1 BC groove 2 (Fig. 3d ), and requires an intact SUFU BH3 sequence ( Fig. 3e ). Thus, several prosurvival BCL-2 proteins can self-regulate their own abundance and their transcriptional regulation activities are required for HH responses.
We wondered whether MCL-1, BCL-2 and BCL-XL function to promote feedforward signalling in an additive or redundant fashion. We first observed that loss of a single protein was sufficient to reduce GLI activity ( Fig. 3f ). Loss of GLI activity here is not a collateral effect from ensuing pro-apoptotic events given these studies were performed in cells lacking the pro-apoptotic BAX and BAK effectors. Pairwise or combined RNA-mediated interference (RNAi) targeting of the three BCL-2 proteins resulted in a modest enhancement of GLI reporter loss as compared with single-gene-focused experiments, suggesting that these genes mostly function in a non-redundant fashion (see Fig. 3f ).
Loss of a single SUFU-interacting prosurvival BCL-2 protein results in increased SUFU stability and decreased expression of GLI target genes in RMS13 cells ( Fig. 3g ). However, removal of the SUFU BH3 sequence by CRISPR-Cas9 editing renders these cells non-responsive to Bcl-2 siRNAs (see Fig. 2h ). On the other hand, Bcl-2 siRNA transfected HAP1 cells (which lack GLI1/GLI2 expression) nevertheless exhibit increased SUFU abundance in a SUFU BH3 sequence-dependent manner but little change in the expression of GLI target genes, thus affirming the requirements of pre-existing GLI1/GLI2 expression for prosurvival BCL-2-dependent transcriptional changes ( Fig. 3h and Supplementary Fig. 3c-e ). We also observed in C3H10T1/2 cells the contribution of the SUFU BH3 sequence to prosurvival BCL-2-dependent transcriptional regulation ( Supplementary Fig. 3f -i).
Given that HH stimulation changes the abundance of MCL-1/ SUFU interactions using a co-IP approach ( Supplementary Fig. 3j -l), we evaluated the effects of deleting MCL-1 on HH signalling in an adult tissue ( Fig. 3i ). Loss of Mcl1 in the murine liver resulted in reduced expression of several HH target genes including Bcl2 and cyclin D1 (Ccnd1). On the other hand, expression of Wnt target genes such as Axin2 and Cmyc was unaffected. Our observations taken together reveal a feedforward GLI signalling mechanism supported by prosurvival BCL-2 protein/SUFU interactions that is sensitive to the abundance of ligands from the BCL-2 family including those that are pro-apoptotic such as NOXA ( Fig. 3j ).
Prosurvival BCL-2 proteins not localized to the mitochondrial membrane regulate SUFU Prosurvival BCL-2 protein family members including MCL-1 are predominantly localized to the OMM via a hydrophobic anchoring sequence found in the carboxy terminus (see Fig. 2a ) 34, 35 . Nevertheless, an MCL-1 protein lacking the anchoring sequence (MCL-1 TM) was able to bind to and inhibit SUFU activity, suggesting that mitochondrial localization is not essential for this activity (see Supplementary Fig. 2a -c). Indeed, prosurvival BCL-2 proteins are found in other subcellular compartments away from the OMM Relative mRNA level mRNA: Supplementary Table 4 . Unprocessed original scans of blots are shown in Supplementary Fig. 7 . Statistical significance was calculated using Student's t-test, * P < 0.05, * * P < 0.01 and * * * P < 0.001.
including in the cytoplasm 35, 36 . We investigated the consequences of removing the TM sequence from MCL-1 or eliminating MCL-1 altogether in C3H10T1/2 cells using CRISPR-Cas9 genome editing ( Fig. 4a,b and Supplementary Fig. 4a,b ). Whereas the two MCL1∆TM cell lines exhibited hyper-responsiveness to exogenously supplied SHH ligand, the Mcl1 −/− cell line exhibited little response (Fig. 4c ). This Table 4 . Unprocessed original scans of blots are shown in Supplementary Fig. 7 .
more robust response was also confirmed using biochemical readouts ( Fig. 4d ). We also evaluated HH responsiveness in a C3H10T1/2 cell line expressing BCL-2 proteins lacking an OMM tether (Fig. 4e,f and Supplementary Fig. 4c ) and observed enhanced response using both the GLI-BS reporter and biochemical approaches ( Fig. 4g,h) . These observations taken together suggest that abundance of cytoplasmically localized BCL-2, MCL-1 and presumably BCL-XL can contribute to cell death resistance by controlling the collective transcriptional regulation of themselves at least in cells with GLI activity (Fig. 4i ).
BH3 mimetics disable GLI transcriptional activity in vivo
Small molecules that target the BC groove of prosurvival BCL-2 proteins (BH3 mimetics) promote apoptosis by disrupting the interaction between prosurvival BCL-2 proteins and their BH3-only partners 37 . To determine whether disabling GLI-mediated transcription using BH3 mimetics can impact cancerous growth, we first identified cancerassociated SUFU mutants that may be refractory to BH3 mimetic response and that could be used to distinguish cell growth effects caused by direct engagement of the pro-apoptotic machinery from effects due to GLI suppression. The overall architecture of SUFU resembles a clamp with N-and C-terminal domains that enables it to latch onto and inactivate GLI proteins 33, 38 (Fig. 5a ). A survey of SUFU mutants across all cancer types using cBioPortal 39, 40 reveals enrichment of mutations in the N-terminal domain and in the IDR (cluster 1 and cluster 2 mutations, respectively; see Fig. 5a and Supplementary Fig. 5a ).
We directly evaluated the ability of several SUFU cluster 1 and 2 mutants to bind MCL-1 using a quantitative co-IP strategy that allows us to normalize interactions with the abundance of associated bait protein ( Fig. 5b; top) . Three out of four IDR mutations compromised (a) SUFU mutants in cancer with potential differential sensitivities to BH3 mimetics. Cancer-associated missense SUFU mutations (cBioPortal) reveal two mutation clusters centred on the N terminus (cluster 1) and the intrinsically disorganized region (IDR; cluster 2). Both mutation sets are distal to β5 and β8, which harbour the GLI1 interaction residues 33 . (b) The majority of SUFU cluster 2 mutations affect SUFU binding to MCL-1. Relative MCL-1/SUFU and GLI1/SUFU interactions were determined using Gaussia luciferase (GL)/firefly (FL) activity ratios in the immunoprecipitated material (n = 3 independent measurements). (c) SUFU mutants that retain responsiveness to a BH3 mimetic. RMS13 SUFU −/− cells transfected with the indicated SUFU DNAs and the GLI-BS and control reporters were cultured with/without ABT-263 (n = 3 independent measurements). (d) SUFU cluster 1 and 2 mutants and their responsiveness to a BH3 mimetic. (e) RMS13 SUFU −/− cells stably expressing SUFU-G64V or SUFU-N328K exhibit similar ability to suppress GLI expression and activity. (f) BH3 mimetics with distinct targeting profiles for MCL-1, BCL-2 and BCL-XL exhibit similar activity profiles in cells expressing either SUFU-G64V or -N328K (n = 3 independent measurements). (g) SUFU-G64V and -N328K cells exhibit similar growth rates in vitro (n = 3 independent measurements). (h) Reducing BCL-2 expression using RNAi mimics the effects of ABT-199 in SUFU-G64Vand -N328K-expressing cell lines. (i) SUFU-N328K exhibits poor ability to bind to prosurvival BCL-2 proteins. (j) ABT-199 prevents growth of SUFU-G64V but not SUFU-N328K cells when subcutaneously transplanted in nude mice (n = 5 mice per group). Scale bar, 20 mm. (k) Quantification of in vivo tumour growth (n = 5 mice per group). (l) ABT-199 suppresses GLI activity in vivo. SUFU-G64V-and SUFU-N328K-expressing tumours from control or ABT-199-treated animals were subjected to quantitative PCR analysis (n = 3 mice per group). All error bars represent mean ± s.d. Source data are available in Supplementary Table 4 . Unprocessed original scans of blots are shown in Supplementary Fig. 7 . Statistical significance was calculated using Student's t-test, * P < 0.05, * * P < 0.01 and * * * P < 0.001.
MCL-1 binding to SUFU, thus confirming the importance of this region for SUFU interaction with prosurvival BCL-2 proteins. However, the majority of SUFU proteins with mutations in either cluster retained to different degrees binding to GLI1 (see Fig. 5b ; bottom). These biochemical results were largely matched by functional tests of mutant SUFU proteins in RMS13 SUFU −/− cells for their ability to suppress GLI activity and to respond to a BH3 mimetic ( Fig. 5c and Supplementary Fig. 5b) .
We next generated cell lines expressing either SUFU-G64V (BH3 mimetic responsive) or -N328K (BH3 mimetic non-responsive) in RMS13 SUFU −/− cells so that we can evaluate the efficacy of BH3 mimetics in blunting cell growth in vivo (Fig. 5d,e ). RMS13 cells exhibit GLI1 overexpression as a consequence of GLI1 gene amplification, thus affording a robust platform for interrogating the mechanistic basis of BH3 mimetic activity against cancer-associated forms of HH pathway induction 41 (Supplementary Fig. 5c ). Both cell lines exhibited similar reduction in GLI1 and BCL-2 proteins, thereby demonstrating their shared capacity to repress GLI (see Fig. 5e ). We also confirmed that other BH3 mimetics such as those targeting BCL-2 (ABT-199) or MCL-1 (MIMX) exhibit a similar GLI response profile in these cell lines and that the cell lines exhibit similar in vitro growth rates ( Fig. 5f,g) . We biochemically confirmed that a BH3 mimetic (ABT-199, which targets BCL-2) or BCL2 siRNAs are able to increase the abundance of the G64V but not the N328K protein and also each protein's ability to interact with prosurvival BCL-2 proteins (Fig. 5h,i) .
We implanted the SUFU-G64V and -N328K cell lines in nude mice and allowed tumours to develop to 30 mm 2 before dosing with the FDA-approved ABT-199 (also known as venetoclax) 37 . Whereas we observed greatly diminished growth of SUFU-G64V cells, the SUFU-N328K cells failed to respond to the drug (Fig. 5j,k and Supplementary Fig. 5d,e ). These observations reveal a previously unappreciated mechanism associated with the anti-cancer activity of BH3 mimetics At the same time, they reveal that a BH3 mimetic targeting a single prosurvival BCL-2 protein can have an effect on the collective expression of the gene class. Indeed, quantitative PCR analysis of RMS13-SUFU-G64V and -N328K tumours in control and ABT-199-treated animals reveals differential responses to ABT-199 exposure with respect to HH pathway target, prosurvival and progrowth genes but not Wnt-pathway-responsive genes (Fig. 5l ). These in vivo observations taken together reveal an ability of BH3 mimetics to inhibit cancerous growth by disrupting GLI transcription.
BH3 mimetics disrupt GLI activity driven by genetic mutations in HH pathway regulators
Despite the recent clinical approval of SMO antagonists for metastatic BCC, anti-cancer strategies premised on targeting SMO suffer from rapidly acquired drug resistance 42 . Many of these mechanisms converge on the emergence of SMO mutations that abrogate drug interaction 43, 44 , or cellular mechanisms that buttress GLI activity even in the presence of SMO antagonists [45] [46] [47] . We evaluated the ability of various BH3 mimetics to disrupt GLI activity induced by cancer-associated alterations of HH pathway components 48 as well as drug-resistance associated mechanisms 49 (Fig. 6a,b and Supplementary Fig. 6a-h) . Although SUFU mutations are infrequent in adolescent/adult medulloblastomas, their prevalence in infant medulloblastomas is common (∼40%) (ref. 11) (see Supplementary   Fig. 6a ). Whereas vismodegib exhibited an activity profile consistent with SMO targeting, the BH3 mimetics retained similar activity against all mechanisms of GLI activation evaluated (see Fig. 6a ). We demonstrated that the BH3 mimetics selectivity profile could be used to predictably disable prosurvival BCL-2 protein/SUFU interactions (Fig. 6c ). Given their attack within the HH pathway at the level of transcriptional regulation, BH3 mimetics may be useful in countering HH-pathway-associated oncogenic changes including those induced by long-term exposure to SMO antagonists.
Consistent with our previous observations, GLI1, BCL-2, MCL-1 and BCL-XL protein abundance was diminished following drug exposure, whereas levels of total and phosphorylated SUFU increased (Fig. 6d) . Notably, chemically induced reduction of BCL-2, MCL-1 and BCL-XL proteins was independent of which prosurvival BCL-2 protein(s) were targeted by the BH3 mimetic applied (see Fig. 6d ), thus confirming the importance of feedforward signalling by interaction between a single prosurvival BCL-2 protein and SUFU to the collective regulation of prosurvival BCL-2 proteins. This feedforward signalling mechanism thus reveals opportunities for disabling cancerous GLI activity using BH3 mimetics that target either a single or multiple prosurvival BCL-2 proteins that interact with SUFU ( Fig. 6e ).
DISCUSSION
Evasion of programmed cell death by heightened expression of prosurvival BCL-2 protein families is a hallmark of cancer 50 . The inhibition of OMM permeabilization by prosurvival BCL-2 proteins has provided the mechanistic rationale for the development of BH3 mimetics as anti-cancer agents, and has served as the major cellular end point assay for monitoring the activity of BCL-2 family proteins. Our identification of a prosurvival BCL-2 recognition sequence in the transcriptional regulator SUFU not only extends the potential utility of BH3 mimetics to include cancers typically associated with mutations in HH pathway components, but also enables the use of GLI target genes as biomarkers of BCL-2 family protein activity in homeostatic and cancerous contexts ( Supplementary Fig. 6i ). Our observations that prosurvival BCL-2 protein/SUFU interactions occur away from the OMM also expands the subcellular reach of BCL-2 proteins and may provide mechanistic insight into the anti-apoptotic activity of prosurvival BCL-2 proteins not found on the OMM [51] [52] [53] . Given the GLI proteins also control the expression of cell proliferation genes such as cyclin D1 (ref. 54 ), our findings also reveal unappreciated pro-growth activities of BCL-2 family proteins.
Our findings also reveal that a subset of the prosurvival BCL-2 proteins (MCL-1, BCL-2 and BCL-XL) collectively self-regulate their own expression levels using the abundance of competing BH3 sequences from BCL-2 family ligands and SUFU as a rheostat in cell death decision-making. It is important to note that this feedforward system is likely to be relevant only in GLI1/2-expressing cells. Indeed, other compensatory transcriptional regulatory loops may control the expression of prosurvival BCL-2 proteins, such as in the case of drug resistance to BH3 mimetics 55 .
We have demonstrated that loss of MCL-1, BCL-2 or BCL-XL results in SUFU accumulation and an increase in the ability of SUFU to bind to GLI proteins. The region that encompasses the PKA and GSK3β phosphorylation sites and the BH3 sequence is intrinsically disorganized but somehow functions as a switch for Supplementary Table 4 and Supplementary Fig. 6 . Unprocessed original scans of blots are shown in Supplementary Fig. 7 . Statistical significance was calculated using Students t-test, * P < 0.05 and * * * P < 0.001.
toggling SUFU conformation 33, 38 . The inability to resolve the structure of the BH3-encoding region in SUFU is reminiscent of canonical BH3 sequences that are similarly unstructured in solution but organize following binding to BCs 56, 57 .
Although ABT-199 (also known as venetoclax) has recently been approved for the treatment of chronic lymphocytic leukaemia 58 , its utility in solid tumours is currently limited 59 . Our study delineates an unconventional path for patient selection in clinical testing of BH3 mimetics predicated on understanding the mutational status of HH pathway components including those associated with resistance to SMO antagonists, and those found in SUFU where these chemicals may function as indirect pharmacoperones. Further studies should reveal the extent to which deviant GLI target gene expression can serve as a predictive biomarker of BH3 mimetic sensitivity in cancers not typically associated with HH signalling.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper.
Note: Supplementary Information is available in the online version of the paper Immunofluorescence. Primary cilia were visualized in cells grown to high density, serum starved overnight (0.5% serum), and stained with anti-acetylated tubulin antibody (T6793, 1:1,000, Sigma) diluted in PBS/0.2% Triton X-100/5% goat serum after fixation in 4% paraformaldehyde (Sigma). Images were collected using a Nikon microscope with a 63× objective.
Covalently coupling antibody to Protein A agarose beads. Anti-SUFU antibody (100 µl) from Cell Signaling Technologies (Cat. No. 2522) was diluted with 10 ml PBS, and mixed with 500 µl Protein A agarose beads by gentle agitation for 60 min at room temperature. Beads were washed twice with 0.2 M sodium borate (pH 9.0) preheated to 50 • C, and suspended into 10 ml 0.2 M sodium borate (pH 9.0). Crosslinking was initiated by the addition of DMP (dimethyl pimelimidate, D8388, Sigma) at a final concentration of 20 mM, and the mixture was incubated for 30 min at room temperature with gentle agitation. The reaction was terminated with a wash using 0.2 M ethanolamine (pH 8.0) (E9508, Sigma), and followed by 2 h incubation at room temperature. Antibody crosslinked beads was then washed three times with PBS and stored in PBS with 0.01% sodium azide (S2002, Sigma).
Immunoblotting and immunoprecipitation. For immunoblotting, cells were lysed in 1× protein sample loading buffer, and proteins were separated on SDS-PAGE (BioRad Criterion TGX Precast Gels). For immunoprecipitation or IgG pulldown studies, cells were lysed in lysis buffer (PBS with 1% NP-40). Cleared lysates were mixed with Protein A agarose beads in the presence or absence of 2 µg of the desired antibody and rotated for 4 h at 4 • C. For immunoprecipitation of endogenous SUFU proteins, cleared lysate from 10 × 15 cm 2 dish cells was mixed with 100 µl Protein A agarose beads covalently coupled with anti-SUFU antibody, and rotated overnight at 4 • C. Beads were then washed three times with lysis buffer. Bound proteins were eluted using 2× protein sample loading buffer and separated on SDS-PAGE. Detailed information for all antibodies used in immunoblotting and immunoprecipitation is provided in Supplementary Table 2 . SUFU-P antibody was provided by S.Y.C. (Nanjing Medical University, China).
In vitro kinase assay. The coding region of human SUFU (residues 27-476) was cloned into a modified pET-28(a) vector (Novagen) that encodes an N-terminal His 6 -tag followed by a recognition site for human rhinovirus 3C protease. The plasmid was transformed into the Escherichia coli strain BL21(DE3), and protein expression was induced by 0.2 mM IPTG at 16 • C overnight. The protein was purified by using a 1 ml HisTrap column (GE Healthcare) and treated with recombinant human rhinovirus 3C protease at 4 • C overnight to remove the N-terminal tag. The protein was further purified by using Resource Q (GE Healthcare) anion-exchange chromatography with a 10 mM to 1,000 mM NaCl gradient elution, followed by gel filtration chromatography using Superdex 200 HR 10/30 (GE Healthcare) equilibrated with the buffer containing 20 mM Tris (pH 8.0), 150 mM NaCl, 10% glycerol and 2 mM dithiothreitol. The purified protein was concentrated and stored at −80 • C. Purified SUFU protein (100 ng) was mixed with Protein A agarose beads bound with control and MCL-1 IgG Fc fusion proteins produced in a 10 cm 2 dish of HEK293 cells. The mixtures were incubated for 4 h at room temperature with gentle agitation. Mixtures were then brought up to 1× kinase reaction buffer (50 mM Tris-HCl, 10 mM MgCl 2 , pH 7.5) and 5 µCi of [γ-32 P]ATP (3,000 Ci mmol −1 ) and 5,000 U of PKAc (NEB) or BSA (Sigma). Mixtures were incubated at 30 • C for 30 min. Samples were then resolved on SDS-PAGE and radiolabelled protein was visualized by autoradiography.
MCL-1 protein expression, SUFU BH3 peptide synthesis, and NMR analysis.
Homogeneously 15 N-labelled human MCL-1 protein was produced in E. coli on the basis of the standard minimal M9 medium protocol using 15 N ammonium chloride 61 . MCL-1 purification and processing with calpain were performed as previously reported to generate cMCL-1 (herein referred to as MCL-1), the stable BC of MCL-1 produced by calpain proteolysis 27 . We previously assigned the backbone 1 H and 15 N resonances of MCL-1 (ref. 4). The human SUFU BH3 peptide, RRLSGKDTEQIRETLRRGLEINSKPVLPPINPQ, was synthesized, HPLC purified, and its molecular weight was confirmed by mass spectrometry ( Supplementary Fig. 2f ) at the peptide synthesis facility of the Hartwell Center for Bioinformatics and Biotechnology at St. Jude Children's Research Hospital. 15 N/ 1 H TROSY NMR titrations of 15 N-labelled cMCL-1 with unlabelled SUFU BH3 peptide were performed at 25 • C in a buffer containing 20 mM phosphate, pH 6.8, and 10% D 2 0 (Cambridge Isotope). The SUFU BH3 peptide stock was prepared at 25 mM in deuterated dimethyl sulfoxide (Chembridge Isotope). The DMSO control titration was performed under the same conditions excluding the peptide. 15 and RMS13 (SUFU ∆BH3 and SUFU KO). In brief, cells were transfected with Cas9 DNA and a sgRNA-expressing plasmid. Cells were clonally selected using puromycin (0.5 µg ml −1 ) for 4 days followed by another 4 days without selection for expansion. Isolated and further expanded clones were used to generate lysates for western blot analysis. Candidate clones were subjected to genomic sequencing using amplicons flanking the sgRNA-targeting site. sgRNA sequences used in the study are available in Supplementary Table 3 .
Mcl1 deletion in liver tissue. Liver tissue was isolated from Mx1-Cre1; Mcl1 fl/fl mice 11 days after three doses of pIpC as previously described 5 .
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Xenograft studies. Female J:NU nude mice (5 weeks old) were purchased from The Jackson Laboratory and housed in accordance with the Institutional Animal Care guidelines. All animal studies were performed in accordance with approved protocols by UT Southwestern Medical Center Institutional Animal Care and Use Committee (IACUC). Mice were divided into four groups of five mice each using power calculation derived from previous outcomes using a similar approach 62 . 1 × 10 7 exponentially growing RMS13 cells were injected subcutaneously into the right flank above the hindlimb of each mouse. Two groups of mice were injected with RMS13-SUFU-G64V cells, and the other two groups with RMS13-SUFU-N328K cells. Ten days post RMS13 cell injection, animals with tumours averaging 4 × 4 mm 2 were randomized into two groups with each group subsequently receiving on a daily basis either 100 mg kg −1 of ABT-199 or vehicle for 18 consecutive days. ABT-199 was formulated for oral dosing in 60% phosal 50 propylene glycol (PG), 30% polyethylene glycol (PEG) 400 and 10% ethanol as described in ref. 63 . Tumour size was measured every other day using a calliper, and tumour volume was calculated using the formula X × Y × Y × 3.1415/6, where X is tumor length and Y is tumor width. The body weights of control and ABT-199-treated animals were recorded every two days for the duration of the study. P values were calculated using two-sided Student's t-test analysis. All data are shown as mean + standard deviation (s.d.). Study participants were aware of control and ABT-199-treated animal group allocation during outcome assessment.
SHH subgroup medulloblastoma gene expression profiling.
The gene expression analysis shown for candidate genes in medulloblastoma and normal cerebellum tissues was compiled from multiple gene expression profiling studies 11, [63] [64] [65] [66] [67] .
Statistics and reproducibility.
All experiments were repeated at least twice unless otherwise indicated. N numbers are indicated in the figure legends. Sample sizes were not predetermined on the basis of statistical power calculation. No formal randomization technique was used. Investigators were not blinded to the group allocation during the experiments. Quantitative data are presented as mean ± standard deviation (s.d.) from at least three independent measurements. Statistical testing was performed using the two-sided Student's t-test. A P value of 0.05 was considered as a borderline for statistical significance.
Code availability. The MAS5.0 algorithm of the GCOS program (Affymetrix Inc.) was used to normalize the medulloblastoma gene expression data. Data were analysed using the R2 software for analysis and visualization of microarray data (see http://r2.amc.nl).
Data availability.
Published microarray data that were reanalysed in this study have been deposited in the Gene Expression Omnibus (GEO) under accession codes GSE49243 11 , GSE12992 61 , GSE10327 67 , GSE37418 63 , GSE3526 66 and EGAS00001001953 62 . The source data for statistical analysis for Figs 1e,f,h, 2l,  3a ,c-f,i, 4c,g, 5b,c,f,g,k,l and 6b, and Supplementary Figs 1a, 2c, 3a ,h,k,l and 5d,e are provided as Supplementary Table 4 . All other data supporting the findings of this study are available from the corresponding author on reasonable request.
In the format provided by the authors and unedited. DOI: 10.1038/ncb3616 Supplementary Table 4 and unprocessed blots in Supplementary Fig. 7 . Supplementary Table 4 and unprocessed blots in Supplementary Fig. 7 . Statistical significance was calculated using Student's t-test, *P < 0.05, **P < 0.01 and ***P < 0.001. Supplementary Table 4 and unprocessed blots in Supplementary Fig. 7 . Statistical significance was calculated using Student's t-test, ***P < 0.001. Supplementary Table 4 and unprocessed blots in Supplementary Fig. 7 for 48 hrs before luciferase activity was measured from cell lysate. (n=3 independent measurements). (i) GLI1 expression as a biomarker for cell lines with a prosurvival BCL-2/SUFU regulatory loop. Cell lines with transcriptome profiles inventoried at the Cell Line Encyclopedia (https:// portals.broadinstitute.org/ccle/home) were ranked ordered with respect to expression of GLI1, a highly validated target gene of GLI protein transcriptional activity. Corresponding expression of SUFU, BCL2, MCL1, and BCLXL for each cell line reveals nearly ubiquitous expression of SUFU and at least one of the three SUFU interacting prosurvival BCL-2 proteins. Note that this approach for identifying cell lines that potentially exhibit SUFU/prosurvival BCL-2 regulation of GLI activity is able to return RMS13 cells which exhibit GLI1 amplification and confirmed SUFU regulation by prosurvival BCL-2 proteins. All error bars represent mean ± s.d. Corresponding author(s): Lawrence Lum
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Describe how samples/organisms/participants were allocated into experimental groups.
No formal randomization techniques was used. Mice were randomly allocated into experimental groups.
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Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Investigators were not blinded to group allocation during data collection and/or analysis.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
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